Lyell Immunopharma, Inc. (LYEL)
| Market Cap | 351.57M -6.0% |
| Revenue (ttm) | 15,000 -63.4% |
| Net Income | -255.16M |
| EPS | -11.31 |
| Shares Out | 24.59M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 236,615 |
| Open | 15.54 |
| Previous Close | 15.64 |
| Day's Range | 14.20 - 15.76 |
| 52-Week Range | 7.20 - 45.00 |
| Beta | -0.09 |
| Analysts | Buy |
| Price Target | 37.63 (+163.15%) |
| Earnings Date | Nov 4, 2026 |
About LYEL
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual‑targeting CD19/CD20 CAR T‑cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy random... [Read more]
Financial Performance
In 2025, Lyell Immunopharma's revenue was $36,000, a decrease of -40.98% compared to the previous year's $61,000. Losses were -$274.45 million, -19.98% less than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for LYEL stock is "Buy." The 12-month stock price target is $37.63, which is an increase of 163.15% from the latest price.
News
Lyell Immunopharma registers to sell 7.43M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 7.43M shares of common stock. The company is not selling any…
Lyell Immunopharma Registration statement: Registration filing
Lyell Immunopharma filed a registration statement on November 13, 2026, providing details about a securities offering with the SEC.
Lyell Immunopharma price target lowered to $39 from $45 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Lyell Immunopharma (LYEL) to $39 from $45 and keeps a Buy rating on the shares. The company’s November 4 update reported a…
Lyell Immunopharma Transcript: Stifel 2026 Healthcare Conference 2026
Ronde-cel showed 91% ORR and 77% CR in the third-or-later-line pivotal trial, with median PFS not reached. A randomized second-line trial is underway, while manufacturing capacity and financing support planned pivotal milestones and BLA submission in 2027.
Lyell Immunopharma Transcript: Goldman Sachs’ RxChange Series: Framing Lyell’s next-generation lymphoma CAR-T data in 4Q
Ronde-cel showed high response rates in second- and third-line lymphoma cohorts, with encouraging durability and safety findings. PiNACLE data are expected mid-2027, with a BLA planned by year-end 2027; a 400-patient head-to-head phase III trial is enrolling.
Lyell Immunopharma price target lowered to $35 from $36 at Stifel
Stifel lowered the firm’s price target on Lyell Immunopharma (LYEL) to $35 from $36 and keeps a Buy rating on the shares.
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor ...
Why Is Lyell Immunopharma Stock (LYEL) Up over 43% Today?
Lyell Immunopharma stock surged over 43% higher on Wednesday after the company announced an $80 million private placement.
Lyell Immunopharma to sell 7.43M shares at $10.77 in private placement
Lyell Immunopharma (LYEL) announced that it has entered into a securities purchase agreement for a private placement of approximately $80M of its common stock. The investors include ARCH Venture Partn...
Lyell Immunopharma Announces $80 Million Private Placement to Advance Ronde-Cel Toward Planned BLA Submission
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor ...
Lyell Immunopharma to Present Positive Updated Ronde-Cel Data in More than 80 Patients at ASH 2026 from PiNACLE Pivotal Trial in 3L+ and from Phase 1/2 2L Cohort in Patients with Relapsed/Refractory Large B-Cell Lymphoma
Ronde-cel achieved a 91% overall response rate and 77% complete response rate; median progression-free survival not reached and estimated 6-month duration of complete response of 92% in 44 patients wi...
Lyell Immunopharma Quarterly report: Q3 2026
Lyell Immunopharma has published its Q3 2026 quarterly earnings report on November 4, 2026.
Lyell Immunopharma Earnings release: Q3 2026
Lyell Immunopharma released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
Lyell Immunopharma To Participate in November Investor Events
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor ...
Lyell Immunopharma Transcript: 2026 Global Healthcare Conference
The session highlighted progress in next-generation CAR T-cell therapies for lymphoma and colorectal cancer, with strong efficacy and safety data for ronde-cel and promising early results for LYL273. Key clinical milestones and regulatory submissions are expected through 2027.
Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor...
Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor...
Lyell Immunopharma reports Q2 net loss ($44.8M) vs. ($42.7M) last year
Cash, cash equivalents and marketable securities as of June 30, 2026 were $228M compared to $247.2M as of December 31, 2025. Lyell believes that its current cash, cash equivalents and…
Lyell Immunopharma Quarterly report: Q2 2026
Lyell Immunopharma has published its Q2 2026 quarterly earnings report on August 6, 2026.
Lyell Immunopharma Earnings release: Q2 2026
Lyell Immunopharma released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Lyell Immunopharma Slides: Company presentation
Lyell Immunopharma has posted slides in relation to its latest quarterly earnings report, which was published on August 6, 2026.
Lyell Immunopharma initiated with a Buy at Stifel
Stifel analyst Stephen Willey initiated coverage of Lyell Immunopharma (LYEL) with a Buy rating and $36 price target The firm believes Rondecabtagene autoleucel is “a best-in-class” autologous CAR T-c...
Lyell Immunopharma initiated with a Buy at B. Riley
B. Riley initiated coverage of Lyell Immunopharma (LYEL) with a Buy rating and $44 price target Lyell is a registrational-stage oncology company with two cell therapy candidates for blood cancer…
Lyell Immunopharma files to sell 1.1M shares of common stock for holders
17:16 EDT Lyell Immunopharma (LYEL) files to sell 1.1M shares of common stock for holders
Lyell Immunopharma Registration statement: Registration filing
Lyell Immunopharma filed a registration statement on July 13, 2026, providing details about a securities offering with the SEC.